You are here

drug launches

Intercept aims to triple sales force as it gears up for potential NASH launch

Intercept aims to triple sales force as it gears up for potential NASH launch

Fierce Pharma

Intercept Pharma

obeticholic acid

Flag link:

Sage's new drug starts slow, as Wall Street waits for depression data

Sage's new drug starts slow, as Wall Street waits for depression data

Biopharma Dive

SAGE Therapeutics

postpartum depression

Flag link:

Pfizer's heart drug impresses with fast US launch

Pfizer's heart drug impresses with fast US launch

Biopharma Dive

Flag link:

Sun Pharma launches CEQUA for treatment of dry eye disease in US

Sun Pharma launches CEQUA for treatment of dry eye disease in US

Pharmaceutical Business Review

dry eye disease

Flag link:

2 Biotechs With Approaching Drug Approvals

2 Biotechs With Approaching Drug Approvals

Motley Fool

Global Blood Therapeutics

sacituzumab govitecan

Flag link:

bluebird bio Prepares for Launch

bluebird bio Prepares for Launch

Motley Fool

beta-thalassemia

Flag link:

FDA-approved Humira copycat from Merck, Samsung Bioepis will wait 4 years to launch

FDA-approved Humira copycat from Merck, Samsung Bioepis will wait 4 years to launch

Endpoints

Samsung Bioepis

Flag link:

Pfizer's keys to juggling 8 U.S. launches? Organization, accountability, clear goals

Pfizer's keys to juggling 8 U.S. launches? Organization, accountability, clear goals

Fierce Pharma

Flag link:

Novartis amps up Symjepi launch to fill Pfizer's EpiPen supply gap

Novartis amps up Symjepi launch to fill Pfizer's EpiPen supply gap

Fierce Pharma

Adamis Pharmaceuticals

Flag link:

First Generic Launch has Significant First-Mover Advantage Over Later Generic Drug Entrants

First Generic Launch has Significant First-Mover Advantage Over Later Generic Drug Entrants

Drug Patent Watch

Flag link:

Catalyst Pharma Focuses on Firdapse Launch & Label Expansion

Catalyst Pharma Focuses on Firdapse Launch & Label Expansion

Yahoo/Zacks.com

Catalyst Pharma

Flag link:

Eyeing a drug launch in early ’20, Esperion lines up a new, $200M funding deal

Eyeing a drug launch in early ’20, Esperion lines up a new, $200M funding deal

Endpoints

Esperion Therapeutics

Flag link:

AbbVie's discounting Humira to aid Skyrizi's launch—and a price war could follow: analyst

AbbVie's discounting Humira to aid Skyrizi's launch—and a price war could follow: analyst

Fierce Pharma

Flag link:

Evolus sparks controversy with Cancun beach bash ahead of Jeuveau launch

Evolus sparks controversy with Cancun beach bash ahead of Jeuveau launch

Fierce Pharma

Flag link:

Getting Clinical On New Drug Launches

Getting Clinical On New Drug Launches

Forbes

clinical trials

Flag link:

Puma Biotech’s new cancer drug Nerlynx suffered a terrible quarter. What gives?

Puma Biotech’s new cancer drug Nerlynx suffered a terrible quarter. What gives?

Fierce Pharma

Puma Biotechnology

Flag link:

Bluebird's not looking to break speed records with its first gene therapy launch

Bluebird's not looking to break speed records with its first gene therapy launch

Fierce Pharma

beta thalassemia

Flag link:

With potential launches nearing, Zai taps investors for $200M

With potential launches nearing, Zai taps investors for $200M

BioCentury

Flag link:

Alexion gets off to the races with key Ultomiris, Soliris launches

Alexion gets off to the races with key Ultomiris, Soliris launches

Fierce Pharma

Flag link:

4 Blockbuster Drug Launches to Watch in 2019

4 Blockbuster Drug Launches to Watch in 2019

Motley Fool

Alexion Pharmaceuticals

Aimmune Therapeutics

rheumatoid arthritis

Flag link:

Pages